Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea L Schaffer

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Journal of Clinical Epidemiology|January 23, 2025
The importance of properly specifying your target trial emulation: commentary on Mésidor et alAndrea L Schaffer, William J Hulme
Kidney International|April 22, 2026
From cutoff to causality: regression discontinuity design for evaluating acute kidney injury e-alertsAndrea L Schaffer, Laurie A Tomlinson
JAMA Internal Medicine|April 20, 2026
Interrupted Time Series Analysis for Policy EvaluationAndrea L Schaffer, Helen J Curtis, Victoria Speed
Pharmacoepidemiology and Drug Safety|October 26, 2017
Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapyAndrea L Schaffer, Nicholas A Buckley, Sallie-Anne Pearson
British Journal of Clinical Pharmacology|June 16, 2016
How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population-based study (2006-2014)Andrea L Schaffer, Sallie-Anne Pearson, Nicholas A Buckley
BMC Medical Research Methodology|March 23, 2021
Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventionsAndrea L Schaffer, Timothy A Dobbins, Sallie-Anne Pearson
Asia-Pacific Journal of Clinical Oncology|February 20, 2021
Real-world data to advance HER2-targeted cancer medicines research: Playing to the strengths of clinical registry and administrative dataMonica Tang, Benjamin Daniels, Andrea L Schaffer, et al.
British Journal of Clinical Pharmacology|March 11, 2020
Patterns of pregabalin initiation and discontinuation after its subsidy in AustraliaTricia Chiu, Jonathan Brett, Sallie-Anne Pearson, et al.
JAMA Network Open|September 19, 2019
Comparison of Prescribing Patterns Before and After Implementation of a National Policy to Reduce Inappropriate Alprazolam Prescribing in AustraliaAndrea L Schaffer, Nicholas A Buckley, Rose Cairns, et al.
Pain|August 12, 2021
Trajectories of pregabalin use and their association with longitudinal changes in opioid and benzodiazepine useAndrea L Schaffer, Jonathan Brett, Nicholas A Buckley, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Journal of Clinical Epidemiology|January 23, 2025
The importance of properly specifying your target trial emulation: commentary on Mésidor et alAndrea L Schaffer, William J Hulme
Kidney International|April 22, 2026
From cutoff to causality: regression discontinuity design for evaluating acute kidney injury e-alertsAndrea L Schaffer, Laurie A Tomlinson
JAMA Internal Medicine|April 20, 2026
Interrupted Time Series Analysis for Policy EvaluationAndrea L Schaffer, Helen J Curtis, Victoria Speed
Pharmacoepidemiology and Drug Safety|October 26, 2017
Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapyAndrea L Schaffer, Nicholas A Buckley, Sallie-Anne Pearson
British Journal of Clinical Pharmacology|June 16, 2016
How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population-based study (2006-2014)Andrea L Schaffer, Sallie-Anne Pearson, Nicholas A Buckley
BMC Medical Research Methodology|March 23, 2021
Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventionsAndrea L Schaffer, Timothy A Dobbins, Sallie-Anne Pearson
Asia-Pacific Journal of Clinical Oncology|February 20, 2021
Real-world data to advance HER2-targeted cancer medicines research: Playing to the strengths of clinical registry and administrative dataMonica Tang, Benjamin Daniels, Andrea L Schaffer, et al.
British Journal of Clinical Pharmacology|March 11, 2020
Patterns of pregabalin initiation and discontinuation after its subsidy in AustraliaTricia Chiu, Jonathan Brett, Sallie-Anne Pearson, et al.
JAMA Network Open|September 19, 2019
Comparison of Prescribing Patterns Before and After Implementation of a National Policy to Reduce Inappropriate Alprazolam Prescribing in AustraliaAndrea L Schaffer, Nicholas A Buckley, Rose Cairns, et al.
Pain|August 12, 2021
Trajectories of pregabalin use and their association with longitudinal changes in opioid and benzodiazepine useAndrea L Schaffer, Jonathan Brett, Nicholas A Buckley, et al.
Pageof 8